Streptozotosin ile deneysel olarak diyabet oluşturulan ratlarda kromun biyokimyasal etkileri

Karbonhidrat, lipid ve protein metabolizmalarında önemli fonksiyonları olan krom, memeliler için temel besin maddelerinden biridir. Krom pikolinat (Cr(pic)3), insüline duyarlı hücre membranlarında etki göstererek insülin etkinliğini reseptör düzeyinde arttırmaktadır. Bu makalede deneysel olarak streptozotosin (STZ) ile Tip 1 diyabet oluşturulan ratların içme sularına 80 μg/kg dozunda krom pikolinat eklenerek serum glikoz, paraoksonaz, insülin, HbA1C düzeyleri ve serum lipid profili üzerine etkilerinin incelenmesi amaçlanmıştır. 30 erkek Wistar Albino rat 4 gruba ayrılmış, diyabet ve diyabet+krom grubuna diyabet oluşturulmak üzere (65 mg/kg) tek doz STZ intraperitonal uygulanmıştır. Diyabet oluşumunu takiben 5 hafta boyunca diyabet+krom ve krom grubundakilerin içme sularına 80 μg/kg dozunda krom pikolinat suda çözünerek eklenmiştir. Elde edilen sonuçlara göre HbA1C düzeyleri diyabet ve diyabet+krom grubundakilerde anlamlı derecede yüksek bulunurken (P

Anahtar Kelimeler:

hayvan modelleri, kan şekeri, karbonhidratlar, krom, diyabet, Diabetes mellitus, diyetler, içme suyu, enzim aktivitesi, yem zenginleştiriciler, insan hastalıkları, insülin, lipit, metabolizma, sıçan

The biochemical effects of dietary chromium in experimental diabetic rats with streptozotocin

Chromium is the main dietary supplement for mammals which has important functions at carbohydrate, lipid and protein metabolisms. Chromium picolinate (Cr(pic)3) may improve insülin sensivity by enhancing intracelluler insülin receptor. In this study we investigated the effects of chromium picolinate at experimental diabetic rats with streptozotocin (STZ). With this purpose serum glucose, insuline, paraoxonase, lipid and HbA1C levels were examined. Thirty male Wistar Albino rats were used which divided into 4 groups. Diabet and diabet+chromium groups were injected STZ intraperitoneally (65 mg/kg). After diabet is formed, Cr(pic)3 was added to drinking water of diabet and diabet+chromium groups (80 μg/kg) for five weeks.. Control and chromium groups had lower serum HbA1C levels than the other groups (P<0.001), but diabet+chromium had lower results than diabet group. Serum paraoxonase levels of diabet group were also lower than the other groups (P<0.01). It means that the activity of paraoxonase is still high in diabet+chromium group in spite of diabet. Insulin levels of diabetic+chromium group were higher than diabetic group which means that chromium may have an effect that increases stimulation of insulin on β cells. As conclusion, chromium is the most searched leading element related with insülin and stimulates insülin receptors or enhances the secretion. In suggestion, it can be supplemented on the diets of diabetic patients.

Keywords:

animal models, blood sugar, carbohydrates, chromium, diabetes, diabetes mellitus, diets, drinking water, enzyme activity, feed supplements, human diseases, insulin, lipids, metabolism, rats,

PDF

___

1. Mertz W: The practical importance of trace elements. A Symphosium Reprinted from Trace Substances in Enviromental Health - XXI, pp. 526-532, 1987.
2. Anderson RA: Chromium. In, Mertz W (Ed): Trace Elements in Human and Animal Nutrition. pp. 225-244, Acedemic Press, New York, 1987.
3. Güneral F: Eser elementler. Katkı Dergisi, 6 (3): 249-250, 1985.
4. Davis CM, Vincent JB: Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochem, 36, 4382-4385, 1997.
5. Mertz W, Roginski EE, Reba RC: Biological activity and fate of trace quantities of intravenous chromium (III) in the rat. Am J Phys, 209, 489-494, 1965.
6. Evans GW: The effect of chromium picolinate on insülin controlled parameters in humans. Int J Bioscie Med Res, 11, 163-180, 1989.
7. Jaouhari JT, Lazrek HB, Jana M: The hypoglycemic activity of Zygophyllum gaetulum extracts in alloxan-induced hyperglycemic rats. J Ethnopharmacol, 69, 17-20, 2000.
8. Eckerson H, Wyte C, La Du B: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet, 35, 1126-1138, 1983
9. Winterhalter KH: Determination of Glycosylated Hemoglobin. In, Antonini E (Ed): Methods in Enzymology. pp. 732-739, Academic Press, New York, 1981.
10. Sümbüloğlu K, Sümbüloğlu V: Man Whitney U Testi. In, Biyoistatistik. Dokuzuncu Baskı, s. 53, Hatiboglu Yayınları, No: 53, Ankara, 2000.
11. Machalinski B, Walczak M, Syrenicz A, Machalinski A: Hypoglycemic potency of novel trivalent chromium in hyperglycemic insülin-deficient rats. J Trace Elem Med Biol, 20, 33-39, 2006.
12. Şahin K, Önderci M, Tuzcu M, Üstündağ B, Sriramoju V, Juturu V: Effect of chromium on carbohydrate and lipid metabolism in a rat model 3 of type 2 diabetes mellitus: The fat-fed, streptozotocin-treated rat. Metabolism, 56 (9): 1233-1240, 2007.
13. Abbott C, Mackness M, Kumar S, Durrington P: Serum paraoxonase activity, concentration and phenotype distribution in Diabetes Mellitus and its relationship to serum lipids and lipoproteins. ATVB, 15, 1812-1818, 1995.
14. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C, Slagboom PE: Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis, 149, 91-97, 2000.
15. Kwiterovich PO: The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol, 82, 13Q-21Q, 1998.
16. Lee J, Prohaska JR, Thiele DJ: Essential role for mammalian copper transporter Ctr 1 in copper homeostasiss and embryonic development. Proc Natl Acad Sci. 98, 6842-6847, 2001.
17. Mackness MI, Arrol S, Abbott C, Durrington PN: The role of high-density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J, 294, 829-834, 1993.
18. Mackness MI, Arool S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high density lipoproteins in protecting low density lipoprotein against lipid peroxidation. The Lancet, 349, 851-852, 1997.
19. Yavuz DG, Deyneli O, Yüksel M, Toprak A, Aydın H, Akalın S: Tip 1 diyabetik hastalarda serum paraoksonaz aktivitesinin endotel fonksiyonu ile ilişkisi, Turk Jem, 7 (Suppl. 1): 2003.
20. Altuntaş Y, Yenigün M: Her Yönüyle Diabetes Mellitus. s. 51-672, Nobel Tıp Kitapevleri, İstanbul, 2001.
21. Okutur K: Tip 2 diabetes mellituslu hastalarda vücut demir depoları ile metabolik kontrol, insülin direnci ve mikroalbuminüri arasındaki ilişki. Uzmanlık Tezi. Şişli Etfal Eğitim ve Araştırma Hastanesi, Dahiliye Polikliniği, İstanbul, 2006.
22. Fox GN, Sabovic Z: Chromium picolinate suplementation for diabetes mellitus. J Fam Pract, 46, 83-96, 1998.
23. Mertz W: Chromium occurrence and function in biologic systems. Phys Rev. Walter Read Army Medical Center, Washington, pp. 163-239, 1969.
24. Liu VJ, Morris JS: Relative chromium response as an indicator of chromium status. AJCN, 31, 972-976, 1983.
25. Yamamato A, Wada O, Ono T: Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem, 165, 627-631, 1987.
26. Lai M, Chen Y, Cheng H: Chromium yeast supplementation improves fasting plasma glucose and LDL-cholesterol in streptozotocin-induced diabetic rats. Int J Vitam Nutr Res, 76 (6): 391-397, 2006.
27. Shindea U, Sharmab G, Xuc Y, Dhallac N: İnsülin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. J Trace Elem Med Biol, 18, 23-32, 2004.